✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals
Market Cap
₹4,611 Cr.
P/E
24.42

Key Ratios

Market cap
Market cap
4,611 Cr
PE
PE
24.42
Prom Holding
Prom Holding
55.22 %
ROE (%)
ROE (%)
12.28
ROCE (%)
ROCE (%)
14.43
Div Yield (%)
Div Yield (%)
0.20
Sales
Sales
2,422 Cr
OPM (%)
OPM (%)
12.23 %
Debt to Equity
Debt to Equity
0.45

About

Aarti Drugs Limited, established in 1984, is part of Aarti Group of Industries with a strong R… Read more
Low
312
52W Range
High
564
  • Aarti Drugs
  • Supriya Lifescience
  • IOL Chem & Pharma
  • TJI Pharma - Small Cap

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statement

New
Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Therapeutic Area Break-Up

Operational Metrics

    Select a Metric
    • APIs Production Capacity (MTPA)
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Brands

    Nizoral

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    Customers

    • Abbott India Ltd.
    • Alembic Pharmaceuticals Ltd.
    • Cipla Ltd.
    • Indoco Remedies Ltd.
    • Kopran Ltd.

    FAQs on Aarti Drugs Ltd. Business

    Aarti Drugs Limited, a key player in the pharmaceutical industry, specializes in manufacturing APIs, Pharma Intermediates, Specialty Chemicals, and Formulations including Ciprofloxacin Hydrochloride and Metronidazole.

    Aarti Drugs major competitors are Supriya Lifescience, IOL Chem & Pharma, Solara Active Pharma, Morepen Laboratories, SMS Pharmaceuticals, Hester Biosciences, Bajaj Healthcare.
    Market Cap of Aarti Drugs is ₹4,611 Crs.
    While the median market cap of its peers are ₹2,956 Crs.

    Aarti Drugs seems to be less financially stable compared to its competitors.
    Altman Z score of Aarti Drugs is 4.43 and is ranked 6 out of its 8 competitors.

    Company Filing

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material